Motivational Enhancement to Improve Treatment Engagement and Outcome in Subjects Seeking Treatment for Substance Abuse - 1

This study has been completed.
Sponsor:
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00032981
First received: April 5, 2002
Last updated: April 13, 2010
Last verified: April 2010
  Purpose

The purpose of this study is to evaluate the therapeutic usefulness of incorporating Motivational Enhancement Treatment into the standard drug abuse treatment entry process of Community Treatment Programs on improving treatment engagement, retention, and outcome.


Condition Intervention Phase
Substance-Related Disorders
Behavioral: Behavior Therapy
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Primary Purpose: Treatment
Official Title: Motivational Enhancement Treatment (MET) to Improve Treatment Engagement and Outcome in Subjects Seeking Treatment for Substance Abuse

Resource links provided by NLM:


Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Drug use
  • Retention
  • HIV risk behaviors
  • Psychosocial functioning

Estimated Enrollment: 561
Study Start Date: May 2001
Study Completion Date: August 2004
Primary Completion Date: August 2004 (Final data collection date for primary outcome measure)
Detailed Description:

Participants seeking treatment at the participating CTPs will be randomly assigned to either "standard" or "MET/MI" treatment, with a 1- and 3-month follow-up. Primary outcome measures will include (1) treatment retention (e.g., number of sessions/weeks completed, the rate of patients completing 3 or more subsequent sessions, and (2) substance use (e.g., urinalyses, days of opioid, cocaine, marijuana, alcohol use, rates of abstinence). Secondary outcomes will include motivation, psychosocial functioning, HIV risk behaviors, treatment utilization, and patient satisfaction. Process assessments will include measures of the working alliance as well as therapist adherence/competence ratings which will evaluate how effectively MET/MI was implemented. Participating CTPs will implement one of two independent protocols, depending on which is the best suited or feasible for the intake procedures at their clinic. Thus, following an invitation to participate, explanation of the study, and provision of informed consent, patients would complete a brief assessment battery followed by either: 1) Random assignment to 3 individual sessions of standard treatment (treatment as usual) at the program versus 3 individual sessions of MET. or 2) Random assignment to 1 individual standard assessment/evaluation session.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Individuals will be eligible for the protocol who:

  • Are seeking outpatient treatment for any substance use disorder
  • Are willing to participate in the protocol (e.g., to be randomized to treatment, be contacted for follow-up assessment, to have their sessions audiotaped)
  • Are able to understand and provide written informed consent

Exclusion Criteria:

Individuals will be excluded who:

  • Are not sufficiently medically or psychiatrically stable to participate in outpatient treatment
  • Are seeking detoxification only, methadone maintenance treatment or residential inpatient treatment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00032981

Locations
United States, California
Haight Ashbury Free Clinics
San Francisco, California, United States, 94117
Tarzana Treatment Center
Tarzana, California, United States, 91356
United States, Connecticut
CT Renaissance, Inc.
Norwalk, Connecticut, United States, 06852
LMG Programs, Inc.
Stamford, Connecticut, United States, 06901
United States, Pennsylvania
Northeast Treatment Center
Philadelphia, Pennsylvania, United States, 19123
Rehab After Work
Philadelphia, Pennsylvania, United States, 19103
Sponsors and Collaborators
Yale University
Investigators
Principal Investigator: Kathleen Carroll, Ph.D. VA Connecticut Healthcare System
  More Information

No publications provided

Responsible Party: Kathleen Carroll, Ph.D., Yale University School of Medicine
ClinicalTrials.gov Identifier: NCT00032981     History of Changes
Obsolete Identifiers: NCT00016770
Other Study ID Numbers: NIDA-CTN-0004-1
Study First Received: April 5, 2002
Last Updated: April 13, 2010
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders

ClinicalTrials.gov processed this record on August 18, 2014